Françoise Meunier, EORTC Director General, discusses issues facing cancer survivors
29 Sep 2014
Prof Françoise Meunier, EORTC Director General, talked to eCancertv during the ESMO 2014 Congress about her recent article in the Financial Times on cancer and financial impact on cancer survivors.
Watch here the video of the interview
Early diagnosis, innovative drugs and integrated therapeutic strategies combining chemotherapy, surgery and radiotherapy have resulted in dramatic increases in cancer survival rates. In fact, EORTC trials have led to long term survival and cure for children with leukaemia and patients with Hodgkin’s lymphoma or testicular and breast cancers.
This success is good news, but it brings with a host of unanticipated issues facing cancer survivors, who are frequently excluded from insurance, mortgages and jobs.
The EORTC is active in addressing these issues. The 1st EORTC Cancer Survivorship Summit facilitated interactions between clinicians, researchers, social workers, patients, insurers, bankers and policy makers, and addressed second malignancies, cardiovascular disease, cognitive dysfunction, infertility/sexuality and psycho-social problems following cancer treatment. In light of the success of the first summit, a 2nd EORTC Cancer Survivorship Summit will be held 31 March – 01 April 2016 in Brussels, and in Spring 2015 the EORTC will organize a special cancer and employment forum for European employers, patients, and politicians.
John Bean, PhD
EORTC, Medical Science Writer
Related News
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Interview of ROSC Chair, Joost Vaerhoeff
28 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
